DOCSLIB.ORG

Cell Cycle Regulators and Hematopoiesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cell Cycle Regulators and Hematopoiesis Oncogene (2002) 21, 3403 ± 3413 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc Cell cycle regulators and hematopoiesis Richard A Steinman*,1 1Department of Medicine and Pharmacology, E1052 BST, 200 Lothrop Street, Pittsburgh, Pennsylvania, PA 15213, USA The cell cycle behavior of hematopoietic cells varies from controls the cell cycle intersect with dierentiation extended quiescence to spectacular proliferation. Cell machinery? cycle regulators choreograph these transitions through variation in the makeup of cyclin-dependent kinase Cell cycle machinery (cdk)-containing complexes and through alteration in protein expression levels and subcellular localization. The The G1-S cell cycle stage represents a critical period mechanisms through which cell cycle regulators couple for cells to commit to growth arrest or proliferation. proliferation, dierentiation and survival is coming into It is during this stage that cells are responsive to sharper focus. Cdk-inhibitors, once thought of solely in cytokines. Once cells are committed to enter S phase, terms of a checkpoint function on cycling, are now additional stimulation by growth factors is super¯uous known to interact directly with proteins and pathways (Sherr, 1994). The following discussion therefore central to dierentiation and apoptosis. By shuttling concentrates on molecular regulators of the G0/G1-S between binding partners committed to discrete func- phase transition, with a particular emphasis on the tional pathways, cell cycle regulators may directly regulatory proteins p21/WAF1/CIP1 (p21) and coordinate proliferation with dierentiation, migration p27Kip1 (p27) that have been widely studied in and apoptosis. hematopoietic models. Oncogene (2002) 21, 3403 ± 3413. DOI: 10.1038/sj/ Both positive and negative regulators guide the onc/1205325 progression of cells into and through G1 phase (Figure 1). Distinct Rb-family-E2F repressor com- Keywords: hematopoiesis; quiescence; cyclin-dependent plexes prevent progression at dierent cell cycle p21 kinases; dierentiation stages ± E2F/p130 sustains cells in G0 phase (Grana et al., 1998; Vairo et al., 1995), whereas a Rb-E2F1 complex suppresses the transcription of genes required for progression through G1 phase phase (reviewed in Mayol and Grana, 1997). As Introduction cells proceed from G0 to S phase, cyclin/cyclin- dependent kinase (cdk) complexes are sequentially Hematopoiesis must be durable and ¯exible throughout activated (Dimri et al., 1996). Cell cycling is the lifespan of an animal. Durability requires a promoted by inactivation of the Rb-E2F1 complex population of stem cells, which continually renew the early in G1 by D-cyclin/cdk-4 or -6 complexes or, diverse pool of progeny in proportions appropriate to later in G1, by cyclin E-cdk2 complexes. Cyclin D their eector functions. Flexibility requires a pool of activity is mitogen-dependent, whereas cyclin E multipotent progenitor cells capable of spectacular activity is mitogen-independent. In hematopoietic proliferation under the spell of siren cytokines. Mature cells, the predominant D cyclins are D2 and D3. cells may be deaf to the proliferative signals of these Cyclin-cdk activity leads to Rb phosphorylation and cytokines yet respond to them with increased eector dissociation of Rb and E2F-1, which can lead to activity. It is likely that the diverse replicative status of activation of genes coding for proteins required for dierent cellular subsets in the marrow is sustained in S phase. The activity of cyclin-cdk's is opposed by part by intrinsic levels of cell cycle regulators, and in cdk-inhibitors (cdki's) of the INK4a class (p15, 16, part by modulation of certain of those regulators by 18, 19 ± inhibitors of cdk4 and 6) or the KIP/CIP environmental cues including cytokines and integrins. family (p21, p27 and p57) which are able to inhibit Drawing from this thesis, this review focuses on cyclins and cdks of multiple types but have greatest current research that illuminates the following ques- inhibitory activity against cdk2 complexes. The anti- tions: What cell cycle regulators primarily control stem proliferative activity of INK4 inhibitors is due in cell quiescence, progenitor replication and cell cycle part to their selective binding to cdk4 and cdk6 exit upon dierentiation? How does the circuitry that complexes and prevention of p21 and p27 seques- tration by those complexes. This results in greater p21 and p27 binding to cdk2, with resultant growth *Correspondence: R Steinman; E-mail: [email protected] arrest. Cell cycle regulator and hematopiesis RA Steinman 3404 Figure 1 Cell cycle control mechanisms. Selected pathways pertinent to cell cycle control in hematopoiesis are highlighted. Inhibition by cdki's prevents cyclin-cdk phosphorylation and dissociation of repressive Rb-E2F complexes The cell cycle status of hematopoietic stem cells IC) (Berardi et al., 1995). Moreover, it has been demonstrated that the LTC-IC activity of primitive An appreciation of the role of cell cycle regulators in cells is highest in G0 phase, and that cells which have hematopoiesis must consider the cell cycle status of cycled and re-entered G0 phase progressively lose their various hematopoietic cell subsets. Regulated expansion pluripotentiality, with little residual activity after three of a small stem cell subset is necessary both to sustain a cyclings (Gothot et al., 1997, 1998a). steady state level of mature blood cells and to upregulate The cell cycle phenotype of primitive cells capable of production in response to stresses such as infection or reconstituting hematopoiesis in mice is controversial, blood loss. These requirements demand either a stem cell however (Srour, 2000). It has been reported that pool capable of constant cycling without a loss of hematopoiesis can optimally be reconstituted by cells pluripotency or a larger population of quiescent stem in G0 phase (Gothot et al., 1998b), in either G0 or G1 cells with limited self-renewal capability that cycle phase (Wilpshaar et al., 2000), or by cells which have sporadically and unpredictably (the clonal succession undergone replication and subsequently entered G1 hypothesis). (but not G0) phase (Glimm and Eaves, 1999). Cells in Most data support a hierarchical organization of S/G2/ or M phase have minimal engraftment potential primitive hematopoietic stem cells (HSC) on the basis (Glimm et al., 2000). Conceivably, there may be a cell of quiescence. According to these studies, primitive cycle-dependence for homing to the bone marrow. hematopoietic cells in G0 phase of the cell cycle exhibit Hematopoietic stem cells (HSC) are functionally the highest stem cell activity (Morrison and Weissman, de®ned by the ability to generate long-term hematopoi- 1994). Two lines of in vitro evidence support this. Bone esis upon transplantation. Alternatively, HSC-enriched marrow cells resistant to cycling in response to c-kit blood subsets often are de®ned on an immunohisto- and IL-3 and surviving 5-¯uorouracil (5FU)-challenge chemical basis in terms of positivity for CD34+ are highly enriched for pluripotent cells capable of (human) or Sca-1 (murine) antigen expression. More generating hematopoietic colonies for prolonged peri- primitive subsets selected for the absence of lineage ods of time (long-term culture-initiating cells, or LTC- markers (CD387 or lin7) are further enriched for Oncogene Cell cycle regulator and hematopiesis RA Steinman 3405 reconstitution potential and reside to a higher degree in progression in HSC). If the cyclin D proteins are the G0 phase of the cell cycle (Leemhuis et al., 1996). produced, a natural question is why the cells are G0 cells are de®ned by 2N DNA content on Hoechst primarily in G0 phase and enter the cycle so slowly. staining and by low metabolic rates (pyronin, or Py-lo, One can envision that stochastic progression into the or Rhodamine, Rh-lo). Functional selection of candi- cell cycle depends on a matrix of expression levels of date stem cells exploits the quiescence of uncommitted, diverse cell cycle regulators. In this view, progression primitive cells by isolating cytokine nonresponsive cells, into the cell cycle depends on permissible combinations often through the use of suicide selection techniques of cell cycle activators and inhibitors aorded by the such as 5-¯uorouracil (5-FU) or 4-hydroperoxycyclo- (random or induced) ¯uctuation of individual protein phosphamide (4-HC) exposure. levels and activities (Gonze and Goldbeter, 2001; The appreciation that signi®cant proportions of Romond et al., 1999). immunophenotypically-isolated stem cell candidates are in G0 phase lent support to the view that the p21WAF1 and HSC's most primitive and pure stem cell populations remained out of the cell cycle, with successive, The cdki's are natural candidates for proteins that stochastic contribution of a portion of these cells to oppose the cell cycle progression of HSC's. The cdki hematopoiesis. Retroviral marking experiments (Capel p21WAF1 has been implicated as playing a predomi- et al., 1990) also lent support to clonal succession of nant role in maintaining hematopoietic stem cell stem cell activity, but have been disputed as an quiescence both in mouse and humans. In subsets of accurate model of steady-state hematopoiesis (Cheshier umbilical cord-derived blood cells enriched for HSC, et al., 1999). the expression of p21 increases concurrently with On the other hand, long-term in vivo BrDU labeling cellular quiescence and HSC phenotype. For instance, experiments indicate that in mice (Bradford et al., although human CD34+ cells are in G0/G1 phase, 1997; Pietrzyk et al., 1985) and to a lesser degree in almost all are negative for p21WAF1 protein expres- primates (Mahmud et al., 2001) hematopoietic stem sion. In contrast, p21WAF1 is expressed in a minority cells are constantly and slowly cycling. In mice of CD34+lin7 cells and is uniformly expressed in the continual BrDU administration demonstrated that 1% of lin7 cells that are cytokine-nonresponsive and Ho-lo/Rho-lo primitive HSC cycle with an average 5FU-resistant (Steinman et al., 1997). Cheng et al. turnover time of 30 days.
Load more

Recommended publications
  • Epithelial Cell Death Analysis of Cell Cycle by Flow Cytometry White Paper
    Epithelial Cell Death Analysis of Cell Cycle by Flow Cytometry White Paper Authors: Savithri Balasubramanian, John Tigges, Vasilis Toxavidis, Heidi Mariani. Affiliation: Beth Israel Deaconess Medical Center Harvard Stem Cell Institute a Beckman Coulter Life Sciences: Epithelial Cell Death Analysis of Cell Cycle by Flow Cytometry PRINCIPAL OF TECHNIQUE Background: Cell cycle, or cell-division cycle, is the series of events that takes place in a cell leading to its division and duplication (replication). In cells without a nucleus (prokaryotic), cell cycle occurs via a process termed binary fission. In cells with a nucleus (eukaryotes), cell cycle can be divided in two brief periods: interphase—during which the cell grows, accumulating nutrients needed for mitosis and duplicating its DNA—and the mitosis (M) phase, during which the cell splits itself into two distinct cells, often called «daughter cells». Cell-division cycle is a vital process by which a single-celled fertilized egg develops into a mature organism, as well as the process by which hair, skin, blood cells, and some internal organs are renewed. Cell cycle consists of four distinct phases: G1 phase, S phase (synthesis), G2 phase (collectively known as interphase) and M phase (mitosis). M phase is itself composed of two tightly coupled processes: mitosis, in which the cell’s chromosomes are divided between the two daughter cells, and cytokinesis, in which the cell’s cytoplasm divides in half forming distinct cells. Activation of each phase is dependent on the proper progression and completion of the previous one. Cells that have temporarily or reversibly stopped dividing are said to have entered a state of quiescence called G0 phase.
    [Show full text]
  • Recruitment of Leukemic Cells from G 0 Phase of the Cell Cycle By
    Leukemia (2003) 17, 2049–2059 & 2003 Nature Publishing Group All rights reserved 0887-6924/03 $25.00 www.nature.com/leu CORRESPONDENCE Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin Leukemia (2003) 17, 2049–2051. doi:10.1038/sj.leu.2403085 were not affected by daunorubicin-induced cell death. To analyze whether a similar cell cycle-specific sensitivity to Ara-C TO THE EDITOR and daunorubicin was observed in other leukemic cell lines, we analyzed four acute lymphoblastic leukemia cell lines and one Although the majority of patients with acute myeloid leukemia CML blast crisis cell line, which were generated in our (AML) responds to initial treatment, relapse of the disease occurs laboratory by culturing of leukemic blasts from five different in a significant percentage of these patients.1 The cell cycle patients in serum-free medium at high cell concentrations until status of leukemic cells may play an important role in the spontaneous sustained proliferation of the leukemic cells response to treatment of leukemic cells. Especially, the broadly occurred. These cell lines cytogenetically and phenotypically used cytotoxic agent Cytarabine (Ara-C) has been demonstrated resembled the primary leukemia. Figure 1b shows the median to exert its action via intercalation into the DNA of cells cell cycle distribution within these cell lines after incubation for À6 specifically in the S phase of the cell cycle, and sensitivity to this 48 h in medium alone, or in medium containing 1 Â 10 M Ara- agent is therefore described to be specific for cells in active cell C or daunorubicin.
    [Show full text]
  • P53 Phosphorylation and Association with Murine Double Minute 2, C-Jun
    [CANCER RESEARCH 60, 896–900, February 15, 2000] Advances in Brief p53 Phosphorylation and Association with Murine Double Minute 2, c-Jun ARF NH2-Terminal Kinase, p14 , and p300/CBP during the Cell Cycle and after Exposure to Ultraviolet Irradiation1 Thomas Buschmann, Victor Adler, Ekaterina Matusevich, Serge Y. Fuchs, and Ze’ev Ronai2 Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029 Abstract though the mechanisms underlying the ability of p53 to elicit such opposing effects are yet to be identified, independent studies point to p53 phosphorylation and association with proteins is implicated in its a different set of p53 regulators and effectors that are affected by p53 stability and activity. We have compared the association of DNA-bound in each of these scenarios. and overall pools of p53 with murine double minute 2 (Mdm2), c-Jun NH -terminal kinase (JNK), p300/CBP, and p14ARF during cell cycle In studying the regulation of p53 stability, we demonstrated previ- 2 ously that, in Swiss 3T3 cells, JNK and Mdm2 target p53 degradation progression. Whereas DNA-bound p53 associates with JNK at G0-G1 and in different phases of the cell cycle (7). In this study, we have with Mdm2 and p300 during S and G2-M phases, the general pool of p53 was found in complex with JNK and Mdm2 almost throughout the cell compared the association of subpopulations of p53 with proteins cycle. Phosphorylation of p53 at serines 9, 15, and 20 is at the highest levels implicated in stability and activity of p53 and monitored the pattern of at G1 and at serines 37 and 392 during G2-M phase.
    [Show full text]
  • A P53-Responsive Mirna Network Promotes Cancer Cell Quiescence Ting La1, Guang Zhi Liu2, Margaret Farrelly1, Nicole Cole3, Yu Chen Feng1, Yuan Yuan Zhang1, Simonne K
    Published OnlineFirst October 9, 2018; DOI: 10.1158/0008-5472.CAN-18-1886 Cancer Tumor Biology and Immunology Research A p53-Responsive miRNA Network Promotes Cancer Cell Quiescence Ting La1, Guang Zhi Liu2, Margaret Farrelly1, Nicole Cole3, Yu Chen Feng1, Yuan Yuan Zhang1, Simonne K. Sherwin1, Hamed Yari1, Hessam Tabatabaee1, Xu Guang Yan1, Su Tang Guo4, Tao Liu5, Rick F. Thorne2,6, Lei Jin7, and Xu Dong Zhang1,2 Abstract Cancer cells in quiescence (G0 phase) are resistant to miRNA-455-3p targeted CDK2-associated cullin domain 1 death, and re-entry of quiescent cancer cells into the cell- (CAC1), which enhanced CDK2-mediated phosphorylation cycle plays an important role in cancer recurrence. Here we of p27 necessary for its polyubiquitination. Of note, the show that two p53-responsive miRNAs utilize distinct but gene encoding miRNA-27b-3p was embedded in the intron complementary mechanisms to promote cancer cell quies- of the chromosome 9 open reading frame 3 gene that was cence by facilitating stabilization of p27. Purified quiescent transcriptionally activated by p53. Similarly, the host gene B16 mouse melanoma cells expressed higher levels of of miRNA-455-3p, collagen alpha-1 (XXVII) chain, was also a miRNA-27b-3p and miRNA-455-3p relative to their prolif- p53 transcriptional target. Collectively, our results identify erating counterparts. Induction of quiescence resulted in miRNA-27b-3p and miRNA-455-3p as important regulators increased levels of these miRNAs in diverse types of human of cancer cell quiescence in response to p53 and suggest that cancer cell lines. Inhibition of miRNA-27b-3p or miRNA- manipulating miRNA-27b-3p and miRNA-455-3p may con- 455-3p reduced, whereas its overexpression increased, the stitute novel therapeutic avenues for improving outcomes of proportion of quiescent cells in the population, indicating cancer treatment.
    [Show full text]
  • Haematopoiesis to Describe the Components of Normal Blood, Their Relative Proportions and Their Functions
    Haematopoiesis To describe the components of normal blood, their relative proportions and their functions Blood 8% of body weight Plasma (55%) clear, 90% water, contains salts, enzymes, proteins WBCs and platelet (1%) RBCs (45%) bioconcave– disc, no nucleus = anuclear- 120days lifespan Immature = blasts– Mature= cytes In white blood cells myeloblast goes to neutrophils, basophils, eosinophils Monoblast= monocyte can also become dendritic cells and macrophages – White blood cells (leukocytes)– Polymorphonuclear= neutrophils, eosinophil s, basophils Mononuclear= lymphocytes= T cells, B cells and’ monocytes Lymphoid= NK cells, T-Lymphocyte, B-lymphocyte Myeloid= Monocyte, erythrocyte, neutrophils, basophils, eosinophils, mast cells, megakaryocyte, mast cells BOTH Dendritic cells (from monocyte in myeloid) (lymphoid precursor) Neutrophil – protection from bacteria and fungi Eosinophil- protection against parasites Basophil – increase during allergic reactions Lymphocytes – T cells- protection against viruses, B cells immunoglobulin synthesis Monocyte- protection from back bacteria and fungi phagocytosis – How do blood go from bone to blood vessels? – The bones are perfused with blood vessels- How do we investigate blood? In venepuncture, the superficial veins of the upper limbs are selected and hollow needle is inserted through the skin into the veins. Blood is then collected into evacuated tubes. These veins are present in numbers and are easily accessible. Anticoagulant, EDTA is used to stop blood clotting 1.Using Automated the sample full collected…. blood count Whole blood for a FBC is usually taken into an EDTA tube to stop it from clotting. The blood is well mixed and put through a machine called an automated analyser, counts the numbers and size of RBC and platelets within the blood using sensors Reticulocyte Assessing the young RBCs numbers performed by automated cell counters give indication of output of young RBC by bone marrow – 2.
    [Show full text]
  • 1 the Potential Role of Cytokines and Growth Factors in the Pathogenesis
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 August 2021 doi:10.20944/preprints202108.0237.v1 The Potential Role of Cytokines and growth factors in the pathogenesis of Alzheimer's Disease Gilbert Ogunmokun1, Saikat Dewanjee2, Pratik Chakraborty2, Chandrasekhar Valupadas3,4 Anupama Chaudhary5, Viswakalyan Kolli6, Uttpal Anand7, Jayalakshmi Vallamkondu8, Parul Goel9, Hari Prasad Reddy Paluru10, Kiran Dip Gill11, P. Hemachandra Reddy12-16 , Vincenzo De Feo17*, ,Ramesh Kandimalla18,19*, 1The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, Houston, Texas, USA 2Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India 3Professor, Internal Medicine & Medical Superintendent, MGM Hospital, Warangal, India 4In charge Medical Superintendent, KMC Superspeciality Hospital, Warangal, India 5Orinin-BioSystems, LE-52, Lotus Road 4, CHD City, Karnal, Karnal, Haryana -132001, India 6Professor, Department of Biochemistry, GITAM Institute of Medical Sciences and Research, Visakhapatnam, India 7Department of Life Sciences and the National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel 8National Institute of Technology, Warangal 506004, Telangana, India 9Department of Biochemistry, Maharishi Markandeshwar Institute of Medical Sciences & Research, Mullana, Ambala, India 10Sri Krsihnadevaraya University, Anantapur, Andhra Pradesh, India 11Department of Biochemistry, Posgraduate Institute
    [Show full text]
  • Neutrophil-Mediated Treatment of Neurodegenerative and Other Inflammatory Disorders Alain L
    RESEARCH ARTICLE Neutrophil-mediated Treatment of Neurodegenerative and Other Inflammatory Disorders Alain L. Fymat Professor, International Institute of Medicine and Science, California, USA ABSTRACT Conventionally, neuroinflammation has been seen as a branch of immunology linked to neurodegenerative and other inflammatory disorders. The diagnosis and treatment of these disorders are dependent on the ability of delivering diagnostic and therapeutic pharmaceuticals through the blood–brain barrier. While itself contributing to the inflammatory process, the barrier largely hinders or even forbids this delivery but allows neutrophils to pass freely through it. This article discusses the use of a nanobiotechnology-based, neutrophil-mediated treatment of neurodegenerative and other inflammatory disorders. Key words: Dopamine, levodopa, paclitaxel INTRODUCTION A schematic representation of the cells and molecules involved in cerebral inflammation is shown in Figure 1. onventionally, neuroinflammation has been seen as The schema summarizes the pathogenic paths that may a central nervous system (CNS) -centric and specific link intravascular inflammatory events to proepileptogenic branch of immunology. Thus, a great deal of effort events in the brain parenchyma. The BBB and its component C cells forming tight junctions are diagrammed by the oblique has been made to find immunocompetent or inflammatory cells in the brain (or spinal cord) parenchyma. The purpose descending gray lines. External activated microglia and of this article is to query whether neutrophils, which pass gliotic astrocytes interact with the BBB being mediated by freely through the blood–brain barrier (BBB), can mediate the interleukin (IL-1β, IL-6, and IL-12) and tumor necrosis factor delivery of diagnostic and therapeutic drugs to the brain to alpha (TNF-α).
    [Show full text]
  • Hematopathology
    320A ANNUAL MEETING ABSTRACTS expression of ALDH1 was analyzed using mouse monoclonal ALDH1 antibody (BD Conclusions: Based on the present results we conclude that miR29ab1 ko’s have Biosciences, San Jose, CA). Correlations between ALDH1 expression and clinical and decreased hematopoietic stem cell population compared to the wild types and that histological parameters were assessed by Pearson’s Chi-square and M-L Chi-square miR29ab1 might have an important role in the maintenance of this cell population. tests. Survival curves were generated using the Kaplan-Meier method and statistical Also, miR29 genes might regulate immunity and life span, since both miR29ab1 and differences by log rank test. miR29ab1/b2c ko’s seem to have markedly decreased life spans. Results: Majority of the tumors (116, 63%) showed stromal staining only, 21 (11%) tumors showed both epithelial and stromal expression, 47 (26%) tumors did not show 1347 The Majority of Immunohistochemically BCL2 Negative FL Grade either epithelial or stromal staining. The normal salivary gland showed epithelial I/II Carry A t(14;18) with Mutations in Exon 1 of the BCL2 Gene and Can expression only. Statistical analyses did not show any correlation between tumor pattern, Be Identifi ed with the BCL2 E17 Antibody tumor size, the presence of perineural invasion and the patterns of ALDH1 expression. P Adam, R Baumann, I Bonzheim, F Fend, L Quintanilla-Martinez. Eberhard-Karls- The survival analysis using Kaplan-Meier method and log rank test did not show any University, Tubingen, Baden-Wurttemberg, Germany. signifi cant differences among the three patterns of ALDH1 expression with survival.
    [Show full text]
  • Blood and Immunity
    Chapter Ten BLOOD AND IMMUNITY Chapter Contents 10 Pretest Clinical Aspects of Immunity Blood Chapter Review Immunity Case Studies Word Parts Pertaining to Blood and Immunity Crossword Puzzle Clinical Aspects of Blood Objectives After study of this chapter you should be able to: 1. Describe the composition of the blood plasma. 7. Identify and use roots pertaining to blood 2. Describe and give the functions of the three types of chemistry. blood cells. 8. List and describe the major disorders of the blood. 3. Label pictures of the blood cells. 9. List and describe the major disorders of the 4. Explain the basis of blood types. immune system. 5. Define immunity and list the possible sources of 10. Describe the major tests used to study blood. immunity. 11. Interpret abbreviations used in blood studies. 6. Identify and use roots and suffixes pertaining to the 12. Analyse several case studies involving the blood. blood and immunity. Pretest 1. The scientific name for red blood cells 5. Substances produced by immune cells that is . counteract microorganisms and other foreign 2. The scientific name for white blood cells materials are called . is . 6. A deficiency of hemoglobin results in the disorder 3. Platelets, or thrombocytes, are involved in called . 7. A neoplasm involving overgrowth of white blood 4. The white blood cells active in adaptive immunity cells is called . are the . 225 226 ♦ PART THREE / Body Systems Other 1% Proteins 8% Plasma 55% Water 91% Whole blood Leukocytes and platelets Formed 0.9% elements 45% Erythrocytes 10 99.1% Figure 10-1 Composition of whole blood.
    [Show full text]
  • 10 Maturation and Development of Leucocytes
    MODULE Maturation and Development of Leucocytes Hematology and Blood Bank Technique 10 Notes MATURATION AND DEVELOPMENT OF LEUCOCYTES 10.1 INTRODUCTION The leucocytes develop from the multipotent hematopoietic stem cell which then gives rise to a stem cell committed to formation of leucocytes. Both these cells cannot be identified morphologically by routine methods. The various types of leucocytes are granulocytes (neutrophils, eosinophils and basophils), monocytes and lymphocytes. The three cell types develop separately and accordingly these processes will be discussed separately. OBJECTIVES After reading this lesson, you will be able to: z explain the various stages in the development of leucocytes. z describe the different types of leucocytes seen normally in PBF. 10.2 MYELOPOIESIS This is the process of formation of myeloid cells. It is restricted to the bone marrow after birth. The committed progenitor cell for granulocytes and monocytes is the GM-CFU which proliferates and differentiates to form myeloblast and monoblast. The myeloblast is the earliest morphologically identifiable cell. It is 10-18µm in size. The cytoplasm is scant and basophilic, usually agranular and may contain a few azurophilic cytoplasmic granules in the blast transiting to the next stage 80 HEMATOLOGY AND BLOOD BANK TECHNIQUE Maturation and Development of Leucocytes MODULE of promyelocyte. It has a large round to oval nucleus with a smooth nuclear Hematology and Blood membrane. The chromatin is fine, lacy and is evenly distributed throughout the Bank Technique nucleus. Two-five nucleoli can be identified in the nucleus. The next stage of maturation is the Promyelocyte. It is larger than a myeloblast, 12-20 µm with more abundant cytoplasm which has abundant primary azurophilic granules .
    [Show full text]
  • Chronic Myeloid Leukemia: a Guide for Patients
    Chronic Myeloid Leukaemia What is chronic myeloid leukaemia? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines CHRONIC MYELOID LEUKEMIA: A GUIDE FOR PATIENTS PATIENT INFORMATION BASED ON ESMO CLINICAL PRACTICE GUIDELINES This guide for patients has been prepared by the Anticancer Fund as a service to patients, to help patients and their relatives better understand the nature of Chronic Myeloid Leukemia (CML) and appreciate the best treatment choices available according to the subtype of CML. We recommend that patients talk to their doctors about the tests or treatments that are needed for their type and stage of disease. The medical information described in this document is based on the clinical practice guidelines of the European Society for Medical Oncology (ESMO) for the management of Chronic Myeloid Leukemia. This guide for patients has been produced in collaboration with ESMO and is disseminated with the permission of ESMO. It has been written by a medical doctor and reviewed by two oncologists from ESMO including the lead author of the clinical practice guidelines for professionals. It has also been reviewed by patients’ representatives from ESMO’s Cancer Patient Working Group. More information about the Anticancer Fund: www.anticancerfund.org More information about the European Society for Medical Oncology: www.esmo.org For words marked with an asterisk, a definition is provided at the end of the document. CML: a guide for patients - Information based on ESMO Clinical Practice Guidelines - v.2013.1 Page 1 This document is provided by the Anticancer Fund with the permission of ESMO.
    [Show full text]
  • Bleeding Fevers! Thrombocytopenia and Neutropenia
    Bleeding fevers! Thrombocytopenia and neutropenia Faculty of Physician Associates 4th National CPD Conference Monday 21st October 2019, Royal College of Physicians, London @jasaunders90 | #FPAConf19 Jamie Saunders MSc PA-R Physician Associate in Haematology, Guy’s and St Thomas’ NHS Foundation Trust Board Member, Faculty of Physician Associates Bleeding fevers; Thrombocytopenia and neutropenia Disclosures / Conflicts of interest Nothing to declare Professional Affiliations Board Member, Faculty of Physician Associates Communication Committee, British Society for Haematology Education Committee, British Society for Haematology Bleeding fevers; Thrombocytopenia and neutropenia What’s going to be covered? - Thrombocytopenia (low platelets) - Neutropenia (low neutrophils) Bleeding fevers; Thrombocytopenia and neutropenia Thrombocytopenia Bleeding fevers; Thrombocytopenia (low platelets) Pluripotent Haematopoietic Stem Cell Myeloid Stem Cell Lymphoid Stem Cell A load of random cells Lymphoblast B-Cell Progenitor Natural Killer (NK) Precursor Megakaryoblast Proerythroblast Myeloblast T-Cell Progenitor Reticulocyte Megakaryocyte Promyelocyte Mature B-Cell Myelocyte NK-Cell Platelets Red blood cells T-Cell Metamyelocyte IgM Antibody Plasma Cell Secreting B-Cell Basophil Neutrophil Eosinophil IgE, IgG, IgA IgM antibodies antibodies Bleeding fevers; Thrombocytopenia (low platelets) Platelet physiology Mega Liver TPO (Thrombopoietin) TPO-receptor No negative feedback to liver Plt Bleeding fevers; Thrombocytopenia (low platelets) Platelet physiology
    [Show full text]